BR0208405A - Compostos de diidropirimina substituìdos com ciano e seu uso para tratar doenças - Google Patents
Compostos de diidropirimina substituìdos com ciano e seu uso para tratar doençasInfo
- Publication number
- BR0208405A BR0208405A BR0208405-8A BR0208405A BR0208405A BR 0208405 A BR0208405 A BR 0208405A BR 0208405 A BR0208405 A BR 0208405A BR 0208405 A BR0208405 A BR 0208405A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- substituted
- treat disease
- dihydropyrimine
- cyan
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 230000000394 mitotic effect Effects 0.000 abstract 2
- WCFAPJDPAPDDAQ-UHFFFAOYSA-N 1,2-dihydropyrimidine Chemical class C1NC=CC=N1 WCFAPJDPAPDDAQ-UHFFFAOYSA-N 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27995601P | 2001-03-29 | 2001-03-29 | |
| PCT/US2002/009497 WO2002079149A2 (en) | 2001-03-29 | 2002-03-26 | Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0208405A true BR0208405A (pt) | 2004-03-30 |
Family
ID=23071059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0208405-8A BR0208405A (pt) | 2001-03-29 | 2002-03-26 | Compostos de diidropirimina substituìdos com ciano e seu uso para tratar doenças |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6809102B2 (enExample) |
| EP (1) | EP1373221A4 (enExample) |
| JP (1) | JP2005504725A (enExample) |
| KR (1) | KR20030086327A (enExample) |
| CN (1) | CN1507435A (enExample) |
| AR (1) | AR034585A1 (enExample) |
| BG (1) | BG108180A (enExample) |
| BR (1) | BR0208405A (enExample) |
| CA (1) | CA2442482A1 (enExample) |
| CZ (1) | CZ20032645A3 (enExample) |
| EE (1) | EE200300474A (enExample) |
| HR (1) | HRP20030875A2 (enExample) |
| HU (1) | HUP0400350A3 (enExample) |
| IL (1) | IL157441A0 (enExample) |
| IS (1) | IS6967A (enExample) |
| MX (1) | MXPA03008634A (enExample) |
| NO (1) | NO20034300L (enExample) |
| PE (1) | PE20021013A1 (enExample) |
| PL (1) | PL373759A1 (enExample) |
| RU (1) | RU2003130961A (enExample) |
| SK (1) | SK11062003A3 (enExample) |
| TW (1) | TWI228416B (enExample) |
| UY (1) | UY27232A1 (enExample) |
| WO (1) | WO2002079149A2 (enExample) |
| YU (1) | YU75803A (enExample) |
| ZA (2) | ZA200306648B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6900214B2 (en) * | 2001-03-29 | 2005-05-31 | Bristol-Myers Squibb Company | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
| PT1847534E (pt) * | 2001-12-11 | 2011-08-01 | Kyowa Hakko Kirin Co Ltd | Derivado de tiadiozolina para o tratamento do cancro |
| WO2006018628A1 (en) * | 2003-03-07 | 2006-02-23 | Astrazeneca Ab | Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer |
| JP3947758B2 (ja) * | 2003-03-07 | 2007-07-25 | アストラゼネカ アクチボラグ | 新規縮合ヘテロサイクル及びその使用 |
| WO2004092147A1 (ja) | 2003-04-18 | 2004-10-28 | Kyowa Hakko Kogyo Co., Ltd. | Ｍ期キネシン阻害剤 |
| CN1802361A (zh) * | 2003-06-10 | 2006-07-12 | 协和发酵工业株式会社 | 噻二唑啉衍生物 |
| US7166603B2 (en) | 2003-07-23 | 2007-01-23 | Bristol-Myers Squibb Co. | Dihydropyrimidone inhibitors of calcium channel function |
| US7157461B2 (en) | 2003-07-23 | 2007-01-02 | Bristol-Myers Squibb Co. | Substituted dihydropyrimidine inhibitors of calcium channel function |
| US20050282838A1 (en) * | 2003-10-16 | 2005-12-22 | Shyamlal Ramchandani | Compounds, compositions, and methods |
| UA84954C2 (ru) * | 2004-07-22 | 2008-12-10 | Astrazeneca Ab | Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования |
| AU2005273705B8 (en) * | 2004-08-18 | 2010-01-28 | Astrazeneca Ab | Enantiomers of selected fused pyrimidones and uses in the treatment and prevention of cancer |
| US20060041128A1 (en) * | 2004-08-18 | 2006-02-23 | Astrazeneca Ab | Selected fused heterocyclics and uses thereof |
| US20100093767A1 (en) * | 2004-12-03 | 2010-04-15 | Takeda San Diego, Inc. | Mitotic Kinase Inhibitors |
| CN101193877A (zh) * | 2005-03-22 | 2008-06-04 | 协和发酵工业株式会社 | 造血系统肿瘤治疗剂 |
| EP1867640A4 (en) * | 2005-03-22 | 2010-07-14 | Kyowa Hakko Kirin Co Ltd | MEANS FOR TREATING SOLID TUMORS |
| JPWO2006137490A1 (ja) * | 2005-06-24 | 2009-01-22 | 協和発酵キリン株式会社 | 再狭窄治療剤 |
| DE102006002065B4 (de) * | 2006-01-16 | 2007-11-29 | Infineon Technologies Austria Ag | Kompensationsbauelement mit reduziertem und einstellbarem Einschaltwiderstand |
| CN110464722B (zh) * | 2019-06-06 | 2023-05-23 | 暨南大学 | 一类小分子化合物或其药学上可接受的盐在制备抗肿瘤转移药物中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6211198B1 (en) | 1993-04-05 | 2001-04-03 | Synaptic Pharmaceutical Corporation | Dihydropyridines and new uses thereof |
| CA2205384C (en) | 1994-11-16 | 2004-06-29 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
| WO1997017969A1 (en) | 1995-11-16 | 1997-05-22 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
| US6172066B1 (en) | 1996-05-16 | 2001-01-09 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
| AU727972B2 (en) | 1996-05-16 | 2001-01-04 | H. Lundbeck A/S | Dihydropyrimidines and uses thereof |
| US6080760A (en) | 1997-06-18 | 2000-06-27 | Merck & Co., Inc. | Alpha 1A adrenergic receptor antagonists |
| WO1998057639A1 (en) | 1997-06-18 | 1998-12-23 | Merck & Co., Inc. | ALPHA 1aADRENERGIC RECEPTOR ANTAGONISTS |
| WO1999025345A1 (en) | 1997-11-14 | 1999-05-27 | Merck & Co., Inc. | Alpha-1a adrenergic receptor antagonists |
| EP1066527A2 (en) | 1998-04-01 | 2001-01-10 | Yale University | Method to identify modulators of survivin - tubulin interaction |
| US6300084B1 (en) | 1998-10-08 | 2001-10-09 | The Regents Of The University Of California | Anti-mitotic agent screening process |
| AUPQ171999A0 (en) | 1999-07-20 | 1999-08-12 | University Of Sydney, The | Neurotropic virus transport |
| DE19935303A1 (de) | 1999-07-28 | 2001-02-08 | Aventis Pharma Gmbh | Oligonukleotide zur Inhibierung der Expression von humanem eg5 |
| DE60028227T2 (de) | 1999-10-27 | 2007-03-29 | Cytokinetics, Inc., South San Francisco | Chinazolinone benutzende verfahren und zusammenstellungen |
| US6617115B1 (en) | 1999-10-27 | 2003-09-09 | Cytokinetics, Inc. | Methods of screening for modulators of cell proliferation |
| US6284480B1 (en) | 2000-04-03 | 2001-09-04 | Cytokinetics, Inc. | Antifungal assay |
| US6900214B2 (en) | 2001-03-29 | 2005-05-31 | Bristol-Myers Squibb Company | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
-
2002
- 2002-03-22 US US10/104,257 patent/US6809102B2/en not_active Expired - Lifetime
- 2002-03-25 PE PE2002000232A patent/PE20021013A1/es not_active Application Discontinuation
- 2002-03-25 TW TW091105771A patent/TWI228416B/zh not_active IP Right Cessation
- 2002-03-26 MX MXPA03008634A patent/MXPA03008634A/es unknown
- 2002-03-26 BR BR0208405-8A patent/BR0208405A/pt not_active IP Right Cessation
- 2002-03-26 WO PCT/US2002/009497 patent/WO2002079149A2/en not_active Ceased
- 2002-03-26 CZ CZ20032645A patent/CZ20032645A3/cs unknown
- 2002-03-26 PL PL02373759A patent/PL373759A1/xx not_active Application Discontinuation
- 2002-03-26 JP JP2002577776A patent/JP2005504725A/ja not_active Withdrawn
- 2002-03-26 SK SK1106-2003A patent/SK11062003A3/sk unknown
- 2002-03-26 CA CA002442482A patent/CA2442482A1/en not_active Abandoned
- 2002-03-26 IL IL15744102A patent/IL157441A0/xx unknown
- 2002-03-26 EP EP02728592A patent/EP1373221A4/en not_active Withdrawn
- 2002-03-26 YU YU75803A patent/YU75803A/sh unknown
- 2002-03-26 CN CNA028074556A patent/CN1507435A/zh active Pending
- 2002-03-26 EE EEP200300474A patent/EE200300474A/xx unknown
- 2002-03-26 KR KR10-2003-7012604A patent/KR20030086327A/ko not_active Withdrawn
- 2002-03-26 HU HU0400350A patent/HUP0400350A3/hu unknown
- 2002-03-26 HR HR20030875A patent/HRP20030875A2/hr not_active Application Discontinuation
- 2002-03-26 RU RU2003130961/04A patent/RU2003130961A/ru not_active Application Discontinuation
- 2002-03-27 UY UY27232A patent/UY27232A1/es not_active Application Discontinuation
- 2002-03-27 AR ARP020101168A patent/AR034585A1/es unknown
-
2003
- 2003-08-26 ZA ZA200306648A patent/ZA200306648B/en unknown
- 2003-09-17 BG BG108180A patent/BG108180A/xx unknown
- 2003-09-18 ZA ZA200307320A patent/ZA200307320B/en unknown
- 2003-09-24 IS IS6967A patent/IS6967A/is unknown
- 2003-09-26 NO NO20034300A patent/NO20034300L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR034585A1 (es) | 2004-03-03 |
| HUP0400350A2 (hu) | 2005-01-28 |
| HUP0400350A3 (en) | 2005-06-28 |
| US6809102B2 (en) | 2004-10-26 |
| KR20030086327A (ko) | 2003-11-07 |
| BG108180A (en) | 2004-09-30 |
| WO2002079149A3 (en) | 2003-02-27 |
| SK11062003A3 (sk) | 2004-08-03 |
| ZA200307320B (en) | 2004-12-20 |
| IS6967A (is) | 2003-09-24 |
| NO20034300L (no) | 2003-11-07 |
| YU75803A (sh) | 2006-05-25 |
| NO20034300D0 (no) | 2003-09-26 |
| WO2002079149A2 (en) | 2002-10-10 |
| IL157441A0 (en) | 2004-03-28 |
| PL373759A1 (en) | 2005-09-05 |
| EE200300474A (et) | 2003-12-15 |
| JP2005504725A (ja) | 2005-02-17 |
| CA2442482A1 (en) | 2002-10-10 |
| EP1373221A2 (en) | 2004-01-02 |
| RU2003130961A (ru) | 2005-04-10 |
| CZ20032645A3 (cs) | 2004-06-16 |
| TWI228416B (en) | 2005-03-01 |
| PE20021013A1 (es) | 2002-11-10 |
| MXPA03008634A (es) | 2003-12-08 |
| HRP20030875A2 (en) | 2004-08-31 |
| ZA200306648B (en) | 2004-11-26 |
| EP1373221A4 (en) | 2004-09-29 |
| UY27232A1 (es) | 2002-11-29 |
| US20030008888A1 (en) | 2003-01-09 |
| CN1507435A (zh) | 2004-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0208405A (pt) | Compostos de diidropirimina substituìdos com ciano e seu uso para tratar doenças | |
| BR0208353A (pt) | Compostos de diidropirimidina substituìdos com ciano e seu uso para tratar doenças | |
| BR0208373A (pt) | Inibidores da tirosina cinase | |
| PA8493701A1 (es) | Compuestos para tratar la obesidad | |
| BR0208192A (pt) | Derivados espirotricìclicos e seu uso como inibidores da fosfodiesterase-7. | |
| BRPI0407834A (pt) | composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase | |
| BR0205829A (pt) | Novas aminas como ligantes dos receptores de histamina-3 e suas aplicações terapêuticas | |
| BR9915210A (pt) | N-aril-amidas de ácido antranìlico-e ácido tioantranìlico | |
| BR9911482A (pt) | Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto | |
| CO5271715A1 (es) | 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa | |
| BR0312232A (pt) | Inibidores de caspases e seus usos | |
| BRPI0007487B8 (pt) | difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase | |
| BR9907270A (pt) | Composto, composição farmacêutica, uso de um composto, e, processos para tratamento ou profilaxia de doenças inflamatórias, por exemplo, asma ou copd, e para a preparação de um composto | |
| BRPI0412893A (pt) | composto, composição farmacêutica, uso de um composto, e, métodos de prevenção, tratamento ou melhora de doenças ou condições inflamatórias, ou doenças ou condições oftálmicas, de tratamento ou melhora de cáncer e para a produção de um composto | |
| BR0309167A (pt) | Composto, processo para a produção de um composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito afetado por uma condição patológica ou doença e produto de combinação | |
| BR0113776A (pt) | Composição de pirrolocarbazóis selecionados fundidos e método para tratar e prevenir várias doenças usando a citada composição | |
| BRPI0418099A (pt) | compostos, composição farmacêutica, e uso de um composto | |
| BR0207526A (pt) | Composto, composição farmacêutica, e, métodos para o tratamento da dor, da enxaqueca, depressão, ansiedade, esquizofrenia, doença de parkinson ou derrame cerebral | |
| BRPI0407253A (pt) | Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos | |
| BRPI0413245A (pt) | compostos heteroarila de 6 membros para o tratamento de distúrbio neurodegenerativos | |
| BRPI0410316A (pt) | composto, composição farmacêutica, uso dos compostos, e, método de tratamento de distúrbios mediados por vr1 e para o tratamento de distúrbios de dores | |
| BRPI0412919A (pt) | combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos | |
| BR0112337A (pt) | Derivados de fosfolipìdeos de ácido valpróico e suas misturas | |
| BRPI0409884A (pt) | compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
| BRPI0411092A (pt) | benzo[b]tiofenos substituìdos com 3-arilsulfanila e com 3-heteroarilsulfanila como agentes terapêuticos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A,7A E 8A ANUIDADES |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2055 DE 25/05/2010. |